Germany rebuffs Aegerion's Lojuxta

Germany's Federal Joint Committee (G-BA) said in a preliminary assessment that Lojuxta lomitapide from Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) has "no additional benefit" to treat homozygous familial hypercholesterolemia (hoFH). G-BA said the company did not submit complete, necessary data. Comments are due April 7, with a final benefit assessment expected in early June. The small molecule microsomal triglyceride transfer protein (MTP) inhibitor is approved in the EU as Lojuxta and in the U.S. as Juxtapid as an adjunct to a low-fat diet and other lipid-lowering therapies. ...